Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
November 09, 2022 07:00 ET
|
Galera Therapeutics
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor...
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
October 26, 2022 13:40 ET
|
Galera Therapeutics
Tumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo at one-year ...
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
September 26, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
September 01, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
August 09, 2022 07:00 ET
|
Galera Therapeutics
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual...
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
June 29, 2022 07:30 ET
|
Galera Therapeutics
Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized, double-blinded, placebo-controlled...
Galera to Present at Jefferies Healthcare Conference
June 02, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
May 26, 2022 17:00 ET
|
Galera Therapeutics
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy Company on...
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
May 16, 2022 07:30 ET
|
Galera Therapeutics
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of...